anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the renal and hepatic subjects, following the screening visit, eligible subjects will return to the study site on Study Day 0 and remain at the site for 2 nights and 2 days. Study drug administration will occur on Study Day 1. Subjects will be discharged on Study Day 2 after the last blood sample has been collected. Subjects will return 7 ± 3 days after dosing with study drug to have final safety assessments performed. For the healthy subjects, following the screening visit, eligible subjects will return to the study site on Study Day 0 and remain at the site for 3 nights and 3 days. Study drug administration will occur on Study Day 1 and Study Day 2. Subjects will be discharged on Study Day 3 after the last blood sample has been collected. Subjects will return 7 ± 3 days after receiving the last dose of study drug to have final safety assessments performed.
Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and "Deqi" and the stimulation apparatus is inefficiency without actual current output.
Trial T0834 was a phase 3, randomized, double-blind, multicenter, placebo-controlled trial designed to evaluate the efficacy of a single oral dose of XOFLUZA compared with placebo in the prevention of influenza in subjects who were household contacts of influenza-infected patients in Japan. Influenza-infected index patients were required to have onset of symptoms for ≤ 48 hours, and subjects (household contacts) were required to have lived with the influenza-infected index patient for ≥ 48 hours.

A total of 715 subjects (XOFLUZA N=360, placebo N=355) 5 years of age and older were randomized and received a single oral dose of XOFLUZA according to body weight and age, or placebo, on Day 1. Subjects received a single dose of XOFLUZA according to body weight. The primary efficacy endpoint was the proportion of household subjects who were infected with influenza virus and presented with fever and at least one respiratory symptom from day 1 to day 10. Influenza infection was confirmed by RT-PCR, fever was defined as a body temperature (axillary) ≥ 37.5°C, and respiratory symptoms were defined as having a symptom of "cough" or "nasal discharge/nasal congestion" with a severity of moderate or severe as assessed by the subject.

The mean age of subjects that were ≥ 5 years of age in Trial T0834 was 35 years; 108 (15%) were 5 to < 12 years, 33 (5%) were ≥ 12 to < 18 years of age, 551 (77%) were ≥ 18 to < 65 years of age, and 23 (3%) were ≥ 65 years of age. All subjects were Asian, 80% were female, and 20% were male.

In subjects that were 5 years of age and older, there was a statistically significant reduction in the proportion of household contacts (subjects) with laboratory-confirmed clinical influenza from 13% in the placebo group to 2% in the XOFLUZA group (see Table 13).

In the 108 pediatric subjects 5 to less than 12 years of age enrolled in Trial T0834, 57 subjects received XOFLUZA and 51 received placebo. In this age group, the proportion of subjects with laboratory-confirmed clinical influenza was 4% in the XOFLUZA group and 14% in the placebo group.
The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
PURPOSE:To obtain a new sulfonamide derivative exhibiting strong inhibiting action against cysteine protease such as calpain, cathepsin B, cathepsin H, cathepsin L and papain. CONSTITUTION:A sulfonamide derivative expressed by the formula I (R is 6-14C aryl or heterocyclic residue which may have one or more substituents) or its salt, e.g. N-phenylsulfonyl-L-leucine-L-valine-methyl ester. The compound of the formula I can be produced e.g. by reacting leucylvaline-methyl ester of the formula II with sulfonyl chloride of the formula III in the presence of a base, reducing the obtained ester compound of the formula IV with a reducing agent to obtain an alcohol of the formula V and oxidizing the alcohol. The compound of the formula I is useful for the treatment of diseases caused by abnormal activation of cysteine protease.
PROBLEM TO BE SOLVED: To reduce burdens when a patient takes medicines back from a pharmacy and to reduce jobs by performing the information and account settlement processings or the like of delivery through an information communication network. SOLUTION: Patient data based on a prescription are transmitted to a computer 105a (S502). The patient data are referred to and the medicines of the patient are prescribed (S503). At the time, a receipt is prepared by using the patient data together with medicine information including the names of the medicines and respective numbers (amounts) (S504) and a seal on which the patient data are written is prepared (S505). The packed medicines on which the seal is stuck and the receipt 400 are sent to a transport company 106 (S506) and delivered to the patient (S507). At the time, the patient is made to sign inside a space 401 (S508). In the pharmacy 103, the receipt 400 is referred to and whether or not the medicines delivered to the patient are erroneous is confirmed.
The present invention relates to the treatment of resistant leukemia. The inventor studied APL cellular heterogeneity by integrating scRNA-seq and scATAC-seq data obtained from PLZF-RARA transformed promyelocytes treated with RA. Establishing cellular clusters and arranging them in hierarchies helped them to identify a subpopulation of transformed promyelocytes that were insensitive to RA-induced differentiation and characterized by a DNA repair gene expression signature and high expression of Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2). Because EZH2 contribution to the pathogenesis of leukemia is contrasted, they further explored EZH2 function in APL development and RA treatment response. They discovered a dual role of EZH2 in APL onset and RA response, suggesting the need to target the non-histone methyltransferase activity of EZH2 for leukemia clearance. Particularly, they showed that the use of an EZH2-selective degrader significantly reduced growth and viability of PLZF-RARA expressing leukemic cells and increased the survival of the mice transplanted with pre-treated leukemia. Thus, the present invention relates to an EZH2 degrader or an inhibitor of the EZH2 gene expression for use in the treatment of resistant leukemia in a patient in need thereof.
The thymus is an energy-consuming organ, and its metabolism changes with atrophy. Testosterone regulates thymus remodeling (atrophy and regeneration). However, the characteristics of the energy metabolism during testosterone-mediated thymic atrophy and regeneration remain unclear. In this study, we demonstrated that testosterone ablation (implemented by immunocastration and surgical castration) induced global metabolic changes in the thymus. Kyoto Encyclopedia of Genes and Genomes pathway enrichment for differential metabolites and metabolite set enrichment analysis for total metabolites revealed that testosterone ablation affected thymic glycolysis, glutamate metabolism, and fatty acid β-oxidation. Testosterone ablation-induced thymic regeneration was accompanied by attenuated glycolysis and glutamate metabolism and changed fatty acid composition and content. Testosterone supplementation in immunocastrated and surgically castrated rats enhanced glutaminolysis, reduced the level of unsaturated fatty acids, enhanced the β-oxidation of unsaturated fatty acids in the mitochondria, boosted the tricarboxylic acid (TCA) cycle, and accelerated thymic atrophy. Overall, these results imply that metabolic reprogramming is directly related to thymic remodeling.
A method for making, storing and using a surgical graft from human amniotic membrane; the resulting graft; and the storage solution.  The amniotic membrane is obtained from human placenta, from which the chorion has been separated. Sheets of the amniotic membrane are cut to size and mounted on filter paper. The cells of the amniotic membrane are killed, preferably while being frozen and thawed in the storage solution. The storage solution comprises a culture medium and a hyperosmotic agent, wherein the hydration of the amniotic membrane is maintained. The membrane can be impregnated with therapeutic agents, prior to storage, for use in post surgical healing or other therapies.
TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
PURPOSE: To prepare microcapsules in a relatively simple and direct way by collecting droplets from a biologically active material contg. polymer droplets formed by atomizing, thereafter coagulating them in a non-solvent and then transferring into a second non-solvent. CONSTITUTION: First, a polymer such as a copolymer of lactic acid and glycolic acid is dissolved in a solvent in which a biologically active material has been dissolved or suspended, to give a soln. or suspension. Then, the soln. or suspension is atomized, then the formed droplets are collected in a non-solvent such as ethanol and an ethanol-water mixture, to coagulate them. Further, the coagulated droplets are transferred into a second non-solvent such as water, to prepare polymeric microcapsules contg. the biologically active material.
The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.
IN BRIEF: Preterm birth is the leading cause of perinatal morbidity and mortality, and new therapies that delay preterm birth and improve neonatal outcomes are urgently needed. This study investigates whether ticagrelor inhibits uterine contractility and inflammation in preclinical in vitro, ex vivo (human) and in vivo (mouse) studies, to explore the potential of repurposing ticagrelor for the prevention of preterm birth.
ABSTRACT: Preterm birth remains a significant global health challenge, affecting approximately 10% of pregnancies and resulting in one million deaths globally every year. Tocolytic agents, used to manage preterm labour, have considerable limitations including lack of efficacy, and adverse side effects, emphasising the urgent need for innovative solutions. Here, we explore repurposing an antiplatelet cardioprotective drug, ticagrelor, as a potential treatment to prevent preterm birth. Ticagrelor has demonstrated pleiotropic actions beyond platelet inhibition, including relaxant effects on smooth muscle cells and anti-inflammatory effects in models of diabetes and sepsis. As preterm birth is underscored by inflammatory processes triggering uterine contractions, these actions position ticagrelor as an attractive candidate for prevention or delay of preterm birth. Utilising primary human myometrial tissue, human myometrial cells, and a mouse model of preterm birth, we investigated ticagrelor's potential as a safe and effective therapy for preterm birth. We showed that ticagrelor did not reduce the frequency or strength of spontaneous muscle contractions of ex vivo myometrial tissue nor did it reduce in vitro inflammation-induced contractility in myometrial cells. Additionally, ticagrelor did not exhibit the anticipated anti-inflammatory effects in myometrial cell culture experiments. In our mouse model of preterm birth, ticagrelor neither improved the preterm birth rate or fetal survival outcomes. Gene expression of pro-inflammatory cytokines and contraction-associated proteins in postpartum mouse uteri were unaltered by ticagrelor. In conclusion, ticagrelor is not a strong candidate to continue investigations in clinical trial for the treatment of preterm labour and prevention of preterm birth.
The invention discloses a paroxetine hydrochloride sustained release tablet and a preparation method thereof. The paroxetine hydrochloride sustained release tablet is prepared from paroxetine hydrochloride, hydroxypropyl methylcellulose and a lubricating agent through the processing steps including preparing materials, mixing, pelleting, total blending, tabletting and packaging by aluminum plastic. The paroxetine hydrochloride sustained release tablet is mainly used for treating symptoms relevant to depression. A novel sustained release preparation is adopted, wherein sustained release refers to the means of delaying the release rate of medicines from the preparation, and reducing the absorption rate after the medicines enter the body, so that relatively stable treatment effect is achieved; the effective blood concentration is kept within relatively long time, the toxic and side effects of the medicines are reduced, and the administration safety is improved. The paroxetine hydrochloride sustained release tablet is convenient to take, and is particularly suitable for patients with chronic diseases who take medicines for a long term, and the compliance of the patients is improved. The paroxetine hydrochloride sustained release tablet has the advantages of good stability, and conveniences in packaging, transportation and storage; the preparation method is simple and feasible, and suitable for industrial production.
In the study, acupressure was applied to the LI4 and HT7 points of the women for approximately 8-11 minutes during the episiotomy repair by BI, one of the researchers who has an acupressure application certificate. The researcher received training and certification in acupressure techniques before starting the intervention.During the episiotomy repair, acupressure was applied by the researcher twice in total. The first acupressure application was started with the first episiotomy suture being placed during the episiotomy repair (with the start of the internal perineal suturing). The second acupressure application was started with the end of the internal perineal suture and the first episiotomy suture of the skin suture. Each application was applied for approximately 4-6 minutes.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for treating or preventing a peripheral neuropathy. An extract of a family Dioscoreaceae for preventing or treating the peripheral neuropathy recovered by extraction of a of the family Dioscoreaceae with a first extraction solvent selected from the group consisting of water, C1-C4 alcohol and a mixture of water and C1-C4 alcohol. The pharmaceutical composition for preventing or treating the peripheral neuropathy. A food composition for preventing or treating the peripheral neuropathy. ^ EFFECT: preparations are effective for treating or preventing the peripheral neuropathy. ^ 8 cl, 9 dwg, 1 tbl, 11 ex
NEW MATERIAL:A phenylacetic ester derivative shown by the formula I [R is H, COR1 (R1 is alkyl, or alkenyl), group shown by the formula II (R2 and R3 are H, lower alkyl, or phenyl; R4 is phenyl which may be replaced with lower alkyl, lower alkyloxy, acyloxy, OH, etc.), group shown by the formula III (A is single bond, 1-2C alkylene, or 1-2C alkyleneoxy; R5 is phenyl which may be replaced with lower alkyl, lower alkyloxy, acyloxy, etc.)]. USE:Having antiphlogistic analgesic action, useful as a nonsteroid antiphlogistic analgesic. Slightly causing side effect such as gastrointestinal disorder followed by occurrence of ulcer. PREPARATION:A compound shown by the formula IV or its reactive derivative is propylene glycol shown by the formula V or its reactive derivative in the presence of a deoxidizer such as pyridine, alkali carbonate, etc. in a solvent such as ether, etc. to give a compound shown by the formula I wherein R is H. This compound is further reacted with a compound shown by the formula R6COOH (R6 is R1, group shown by the formula VI, or -A-R5), to give the compound shown by the formula I wherein R is other than H.
The invention discloses a lignum sappan medicated liquor. Each 50kg of the lignum sappan medicated liquor comprises 450-550g of lignum sappan, 200-300g of Japanese stephania root, 70-130g of Himalayan creeper herb, 300-400g of Xiaomajian, 200-300g of cortex eucommiae, 200-300g of liparis nervosa (Thunb.) Lindl., 300-400g of common jasminorange leaf and twig, 50-100g of gonatanthus pumilus, 200-300g of Xiulan, 250-350g of Philippine flemingia root, 30-70g of Shema Zhuhong and 70-130g of rhizoma anemones raddeanae. The invention further discloses a medicated glutinous rice ball containing the lignum sappan medicated liquor. Through regular external application, the lignum sappan medicated liquor is capable of relieving vertebral spur, obstruction of meridians and collaterals, traumatic injury and all rheumatism diseases obviously and curing patients with mild symptoms. The lignum sappan medicated liquor is simple in preparation method, low in cost and good in treatment effect, and raw materials are available.
This is a randomized, observer-blind, single-center, supervised, controlled, parallel-designed study. Approximately 90 generally healthy adults meeting the necessary inclusion/exclusion criteria will be enrolled so that 78 subjects (26 per treatment group) would reasonably be expected to complete the study. Subjects will have their oral soft/hard tissues assessed at Screening (visit 1), Baseline (visit 2), and Days 3, 5, 24, and 25 (visits 4,6-8). During the first week of the study, subjects will be instructed to brush their teeth for one minute in their usual manner, twice daily using the provided standard fluoride toothpaste. Subjects will return for the Baseline exam and, upon qualification with entry criteria, will be assigned to one of three treatment groups. Qualified subjects will be instructed to return to the site for five consecutive days. Subjects will have four supervised rinses with their assigned mouth rinse for either 30 or 60 seconds using 10 ml or 20 ml, at subsequent one-hour intervals. During the 5 consecutive days of exposure to the assigned mouthrinse, subjects will brush their teeth using the provided fluoride-free toothpaste and soft-bristled toothbrush.

Subjects will then have an 18-day rest period (off treatment). During this time, subjects will follow their usual oral hygiene and dietary habits, using the standard fluoride toothpaste and soft toothbrush provided, and must refrain from using any unassigned oral care products. On the 19th day after completion of Day 5 (Day 24), subjects will return for an oral examination. If no pathology is present, subjects will be given a challenge treatment (four supervised rinses) and the final oral examination will be performed on Day 25.
BACKGROUND: Regional anesthesia ("block") is an important component of upper extremity (UE) surgery pain control. However, little is known about patient experience related to perioperative opioid use. This study assessed patient-reported pain control and satisfaction with UE blocks and evaluated how opioid consumption impacted these outcomes before the block "wore off."
METHODS: A postoperative phone survey was administered to patients who underwent outpatient UE surgery at a surgery center for more than 16 months. It assessed pain scores (scale 1-10), satisfaction with block duration (scale 1-5), duration until return of UE function, and opioid consumption. Analyses used Mann-Whitney U tests, Fisher exact tests, and bivariate and multivariable linear and ordered logistic regressions to understand relationships between opioid use and outcomes.
RESULTS: A total of 509 patients (61%) completed the survey, and 441 (88%) were satisfied with block duration. Initial and final pain scores were significantly higher in patients who took opioids prior to the block wearing off (6 and 4.5, P = .04 and 3.5 and 2, P = .002, respectively). Although satisfaction with block duration was not different in group comparisons (ie, patients who premedicated vs those who did not), in a multivariable analysis, patients who premedicated with opioids had 78% increased odds of reporting the highest level of satisfaction compared with the lower 4 levels (P = .03).
CONCLUSIONS: Upper extremity blocks are associated with high overall patient satisfaction and postsurgical pain control. Premedicating before the block wears off may increase patient satisfaction with block duration even if pain is not notably impacted.
Biodegradable shape memory polymer compositions, articles of manufacture thereof, and methods of preparation and use thereof are described. In one embodiment the compositions include at least one hard segment and at least one soft segment. The T trans of the hard segment is preferably between -30 and 270 .degree.C. At least one of the hau l or soft segments can contain a cross-linkable group, and the segments can be linked by formation of an interpenetrating network or a semi - interpenetrating network, or by physical interactions of the segments. Objects can be formed into a given shape at a temperature above th e T trans of the hard segment, and cooled to a temperature below the T trans of the soft segment. If the object is subsequently formed into a second shape, the object can return to its original shape by heating the object above the T trans of the soft segment and below the T tra ns of the hard segment.